There are 3163 resources available
Can artificial intelligence improve early detection of cardiotoxicity after breast cancer treatment
Presenter: Tanja Spanic
Session: The future of cancer via patient expertise in research & innovation projects
Resources:
Slides
Webcast
Panel discussion / Q&A
Session: ESMO in collaboration with the MASCC: Shedding light on the hidden microbiota
Resources:
Webcast
Invited Discussant 714MO, 715MO, 716MO and 717MO
Presenter: Kathleen Moore
Session: Mini oral session 2: Gynaecological cancers
Resources:
Slides
Webcast
Q&A
Session: Proffered paper session 2: GI tumours, lower
Resources:
Webcast
Coffee break
Session: YO Masterclass: Designing v2.0 clinical trials
Resources:
Webcast
1596O - Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): An ancillary study of the STAMPEDE docetaxel trials
Presenter: Emily Grist
Session: Proffered paper session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA26 - SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
Presenter: Kimmie Ng
Session: Proffered paper session 2: GI tumours, lower
Resources:
Abstract
Slides
Webcast
718MO - Mirvetuximab soravtansine (MIRV) in recurrent platinum-sensitive ovarian cancer (PSOC) with high folate receptor-alpha (FRα) expression: Results from the PICCOLO trial
Presenter: Angeles Secord
Session: Mini oral session 2: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
610O - Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6
Presenter: Manish Patel
Session: Proffered paper session 2: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1078MO - Pembrolizumab (pembro) vs placebo as adjuvant therapy for high-risk stage II melanoma: Long-term follow-up, rechallenge, and crossover in KEYNOTE-716
Presenter: Jason Luke
Session: Mini oral session: Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast